Gosset CARD-BCL10-MALT1 signalosome complex Overview
The **CARD-BCL10-MALT1 (CBM) signalosome complex** is a multiprotein assembly that acts as a critical signaling hub downstream of antigen receptors in lymphocytes and some myeloid and non-immune cells. It comprises a CARD-coiled-coil protein (such as CARD11/CARMA1, depending on cell type), BCL10, and mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1). Upon antigen receptor activation, this complex recruits and activates ubiquitin ligases and kinases, primarily leading to activation of the NF-κB transcription factor. This signaling is essential for lymphocyte activation, proliferation, and survival. Dysregulation or mutations in CBM components are implicated in lymphoma, immune deficiencies, and other immune-related disorders. The CBM signalosome is considered a promising therapeutic target, with ongoing efforts to develop MALT1 protease inhibitors for certain lymphomas and immune diseases[1][2][3][4][5].
Mechanism of Action
Inhibition of MALT1 protease to block downstream NF-κB activation and suppress aberrant lymphocyte signaling
Biological Functions
Disease Associations
Safety Considerations
- Potential for immunosuppression (risk of infection, compromised immune responses) if the CBM signalosome is inhibited
- Off-target effects due to complex’s central signaling role
Interacting Drugs
Associated Biomarkers
| Biomarker |
|---|
| Mutations in CARD11, BCL10, or MALT1 can serve as biomarkers for certain lymphoid malignancies or immune disorders |